5485-91-6

Upstream product

• 1503-53-3 2-acetyloxy-5-bromobenzoic acid 
• 89-55-4 5-bromosalicyclic acid 

Downstream Products

• 55981-17-4 2-acetoxy-5-bromo-N-(5-nitro-thiazol-2-yl)-benzamide 
• 6329-74-4 5-bromo-2-hydroxybenzamide 
• 7120-43-6 5-chlorosalicylamide 
• 1237514-87-2 tert-butyl 2-(2-acetoxy-5-bromobenzamido)-4-phenylbenzoate 
• 1237514-96-3 methyl 2-(2-acetoxy-5-bromobenzamido)-4-phenylbenzoate 
• 1237519-45-7 C₃₂H₂₉NO₅ 
• 1237519-42-4 C₂₄H₂₂BrNO₄ 
• 1237515-10-4 2-(5-(6-aminopyridin-2-yl)-2-hydroxybenzamido)-4-phenylbenzoic acid 
• 1237519-49-1 tert-butyl 2-(5-(6-aminopyridin-2-yl)-2-hydroxybenzamido)-4-phenylbenzoate 
• 1237515-09-1 tert-butyl 2-(2-acetoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)-4-phenylbenzoate 
• 1237515-05-7 2-(5-(furan-2-yl)-2-hydroxybenzamido)-4-phenylbenzoic acid 
• 1237519-47-9 methyl 2-(2-acetoxy-5-(furan-2-yl)benzamido)-4-phenylbenzoate 
• 1237515-04-6 2-(2-hydroxy-5-phenylbenzamido)-4-phenylbenzoic acid 
• 1237519-46-8 tert-butyl 2-(2-hydroxy-5-phenylbenzamido)-4-phenylbenzoate 

Relevant academic research and scientific papers

Synthesis and antioxidant activities of berberine 9-: O -benzoic acid derivatives

Although berberine (BBR) shows antioxidant activity, its activity is limited. We synthesized 9-O-benzoic acid berberine derivatives, and their antioxidant activities were screened via ABTS, DPPH, HOSC and FRAP assays. The para-position was modified with halogen elements on the benzoic acid ring, which led to an enhanced antioxidant activity and the substituent on the ortho-position was found to be better than the meta-position. Compounds 8p, 8c, 8d, 8i, 8j, 8l, and especially 8p showed significantly higher antioxidant activities, which could be attributed to the electronic donating groups. All the berberine derivatives possessed proper lipophilicities. In conclusion, compound 8p is a promising antioxidant candidate with remarkable elevated antioxidant activity and moderate lipophilicity.

Design, synthesis and activity evaluation of N-(pyridin-4-yl) salicylamides as antimycobacterial agents

A series of N-(pyridin-4-yl) salicylamides derivatives were prepared through acylation of the corresponding acetylsalicyloyl chlorides with substituted 4-amino-pyridines. These compounds were evaluated in vitro for antimycobacterial activities against Myc

N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF

An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or the like; R2 represents a hydrogen atom or the like; R3 represents an optionally substituted aryl group or the like; X1 represents a carbonyl group; X2 represents a bonding hand; X3 represents a bonding hand; X4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.)

N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF

An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or th

ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

A highly practical route to 2-methylchromones from 2-acetoxybenzoic acids

2-Methylchromones were accessed via a keto ester condensation on 2-acetoxybenzoyl chloride, followed by cyclization and decarboxylation. No column chromatography was required in the process.

Novel quinolizidine salicylamide influenza fusion inhibitors

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).

Benzopyrones. Part 23. Cyclization of o-Amino Carboxamides and Related Compounds

Cyclization of 2-amino-6-bromo-4-oxochromene-3-carboxamide (5) with diethyl oxalate-sodium ethoxide gave the benzopyranopyrimidine-4,6-dione (6).Ethyl 3-amino-2-carbamoyl-4-oxochromene-6-carboxylate (10a) in a similar reaction gave derivatives of a